Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A Registry for Patients With Chronic Hypoparathyroidism

Trial Profile

PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A Registry for Patients With Chronic Hypoparathyroidism

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Jan 2019

At a glance

  • Drugs Parathyroid hormone (Primary)
  • Indications Hyperparathyroidism
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms PARADIGHM
  • Sponsors Shire
  • Most Recent Events

    • 21 Nov 2018 Planned End Date changed from 30 Jun 2035 to 30 Nov 2034.
    • 21 Nov 2018 Planned primary completion date changed from 30 Jun 2035 to 30 Nov 2034.
    • 22 May 2018 Study design presented at the 20th European Congress of Endocrinology (ECE 2018), according to a Shire plc media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top